The Association for Value-Based Cancer Care’s (AVBCC) podcast series addresses the ever-evolving
landscape of value related to cancer care in the United States. Our goal is to foster informed dialogue, promote transparency, and empower all players to navigate the rapidly changing landscape of cancer care with clarity and confidence.
Medicare Advantage, AI, MFN, China, and Consensus Building: Powerful Insights from HLC
Value-Based Voices welcomes Maria Ghazal, JD, MA, President & CEO, Healthcare Leadership Council, for a dynamic conversation spanning Medicare Advantage, prior authorization reform, artificial intelligence, Most Favored Nation drug pricing, and the growing competitive pressure from China in biopharmaceutical innovation. During this conversation, hosted by Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, Maria shares insights from HLC’s diverse membersh...
29 Sept 2026
Who Gets Access? Understanding the New Reality of Cancer Drug Coverage
Are oncology treatments losing their "special status" with payers? In this episode of Value-Based Voices, host Brian Reid, MS, Principal of Reid Strategic and author of the Cost Curve newsletter, sits down with James Chambers, PhD, MSc, MPharm, Professor at Tufts University School of Medicine and Director of the Specialty Drug Evidence and Coverage (SPEC) Database, to examine how payer coverage decisions are shaping access to cancer therapies in the United States. Drawing on nearly a ...
25 Sept 2026
AI at the Point of Care: Inside OpenEvidence's Approach to Smarter Clinical Decisions
Artificial intelligence is rapidly reshaping healthcare, but what does that look like in the day-to-day practice of oncology? In this episode of AVBCC's Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sits down with Samyukta Mullangi, MD, MBA, Medical Oncologist at Tennessee Oncology and Vice President of Clinical Strategy at OpenEvidence, to discuss how AI-powered clinical decision support tools are helping clinicians navigate an...
1 Sept 2026
From Patient to Person: Redefining Cancer Care at the AVBCC LA Regional Collaborative
In this episode of Value‑Based Voices, host Deirdre “Dee” Saulet, PhD, Chief Strategy Officer, Jasper Health, and AVBCC Southwest Regional Collaborative Co-Chair, sits down with two extraordinary guests, Kommah "Koko" McDowell, MS, a 21‑year survivor, nationally recognized advocate, and Chief Customer Officer at Tali Health, and Leon Cristobal, MPH, an eight‑year leukemia survivor, and Oncology Sales Consultant, Bayer. Recorded following the AVBCC Regional Collaborative in Los Angeles, this ...
25 Aug 2026
Red Tape: Real Consequences for Patients with Cancer
What happens when patients with cancer spend weeks navigating insurance requirements before receiving physician-prescribed care? In our latest episode of Value-Based Voices, Brian Reid, Principal of Reid Strategic and author of the Cost Curve newsletter, and Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sit down with Cancer Care's Alexandra Zaleta, PhD, VP of Research & Insights, and Kim Czubaruk, JD, VP of Policy, to discuss findings from Can...
11 Aug 2026
Part D Upheaval: Why the Cancer Community Needs to Pay Attention
In this episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sits down with Joel White, Partner and Head of Health Practice at Monument Advocacy, and a principal architect of Medicare Part D, to discuss one of the most consequential challenges facing cancer care today: the end of the Part D Premium Stabilization Demonstration. Bringing unmatched historical insight, policy fluency, and practical clarity to the conversat...
4 Aug 2026
Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation
In this follow up conversation, Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies and AVBCC Board Members, and Steve Usdin, Senior Editor, Washington, BioCentury Publications, take a clear eyed look at the future of the FDA and the forces shaping biopharmaceutical innovation. Building on their earlier discussion of FDA history and political dynamics, Steve offers candid insights into how U.S. policy, global competition - particularly with China - and shifting regulatory priorities ...
28 Jul 2026
The Future of the FDA: What Comes Next?
In this first of a 2-part series featuring Steve Usdin, Senior Editor, Washington, BioCentury Publications, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies and AVBCC Board Member, leads a spirited conversation around developments at the FDA, the political influence shaping its decisions, and the outlook for the future. Key topics covered include: The state of morale among FDA career staff and the challenges in attracting new talentEroding confidence levels within...
30 Jun 2026
Reflections on the NCCN
In this episode of Value-Based Voices, we delve into the mission and inner workings of the NCCN, a cornerstone organization shaping cancer treatment standards in the U.S. and beyond. We're joined by Bill McGivney, PhD, Principal, McGivney Global Advisors, and Former CEO, NCCN; and host Nicolas Ferreyros, Managing Director, Policy, Advocacy, and Communications, Community Oncology Alliance. Hear expert insights on how guidelines, payer decisions, and evolving technologies influence patien...
16 Jun 2026
Advancing Cancer Research and Innovation through Collaboration at GCRIS 2026
We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices. Join GCRIS Scientific Co-chairs Stan Skrzypczak, MS, MBA, Managing Partner, 5 Prime Life Science Consulting, and Nick Sarlis, MD, PhD, FACP, Chief Medical Officer, Cleara Biotech, as they talk with GCRIS Co-chair Matt Vossler, Managing Director, DSG Global, about the groundbreaking science, innovative drug development, and collaborative ecosystems t...
2 Jun 2026
Breaking the Model: Can Value-Based Insurance Deliver?
Most cancer drugs today are more effective and accessible than ever—yet patients often face crushing costs because our healthcare system still values profit over patient benefit. What if the key to transforming cancer care affordability lies in rethinking insurance design, reforming PBMs, and empowering employers with transparent data? In this eye-opening episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board o...
19 May 2026
From the Human Genome Project to 48 Hours: The Rapid Evolution of Tumor Biology
Most treatments and diagnostics once took years and hundreds of millions of dollars. Today, it costs less than $100,000 to sequence a genome and open the door to tailored cancer therapies that could save lives. But understanding tumor biology is only half the battle. The real challenge lies in interpreting complex genetic data quickly, accurately, and at scale. In this episode of AVBCC’s Value-Based Voices, James Hamrick, MD, MPH, Chair, Precision Oncology Alliance at Caris Life Sciences, tea...
30 Apr 2026
Navigating Value and Policy in U.S. Cancer Care and Pharma Pricing
International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, join Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, and healthcare policy strategist Brian Reid, MS, Founder of Reid Strategic, as they unpack the complex debate over the proposed international MFN models like Globe, Guard, and Generous — and whether they will do m...
14 Apr 2026
Most Favored Nation and What's Next
Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America? In this episode of Value-Based Voices, Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Benchmark could reshape how medicines reach patients, providers, and payers. You’ll discover ...
17 Mar 2026
AI Revolution: Breaking Pharmacy Chains with Harry Travis, BS Pharm, MBA, and Ira Klein, MD, MBA, FACP
There are countless opportunities hidden in the data-driven tasks pharmacists do every day, and AI is ready to unlock them. But what happens when automation dramatically increases productivity in pharmacy, and how do regulations, workforce, and patient care evolve in tandem? In this latest episode of AVBCC's Value-Based Voices, join Ira Klein , MD, MBA, FACP, VP Medical Affairs, Payer Relations, Tempus Labs, and AI innovator Harry Travis, BS Pharm, MBA, President, The Travis Group, LLC, as th...
24 Feb 2026
Consolidation Versus Independence in Cancer Care
Is consolidation in cancer care truly the best path forward, or does independence offer greater benefits? In this episode of Value-Based Voices Sarah Alwardt, PhD, President, Avalere Health, and Jeff Patton, MD, CEO, OneOncology, discuss the nuances of consolidation versus independence in cancer care, the impact of policy and capital access, and the future of value-based oncology. Gain insights into sustainable models, data utilization, and patient-centered strategies. Contact Value-Based Vo...
8 Feb 2026
Insights from JP Morgan 2026 with Liz Fowler, PhD, JD
Commercial health plans may have been missing from J.P. Morgan 2026, but government had a big presence! Value-Based Voices host Burt Zweigenhaft, PhD, and nationally recognized health policy expert Liz Fowler, PhD, JD, share their observations from this year’s meeting and key insights around most-favored nation prescription drug pricing, 340B, PBMs, Medicare site neutrality, AI, and of course value-based care. Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podca...
8 Feb 2026
More Insights from JP Morgan 2026 with Jeff Berkowitz, JD
Where was the drama at JP Morgan this year? Host Burt Zweigenhaft, PhD, and seasoned healthcare executive Jeff Berkowitz, JD, debate why the 2026 meeting seemed to be missing its normal electricity. They also share their thoughts around challenges with direct-to-patient models, most-favored-nation and its impact on product launch and pricing both in the US and Europe, and how AI may or may not be the key to finally achieving value-based outcomes. Contact Value-Based Voices - Follow AVBC...
Contact AVBCC Value-Based Voices
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of AVBCC Value-Based Voices?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
